Group 1 - China State Construction won multiple major projects with a total amount of 21.53 billion yuan, accounting for 1.0% of the audited revenue for 2024 [1] - Zhongtai Chemical's subsidiary has fully launched a methanol upgrading demonstration project, which will further reduce production costs [1] - Wide Special Materials expects a net profit increase of approximately 367.51% year-on-year for the first half of 2025, driven by improved demand and internal optimization [1][2] Group 2 - Longdi Group plans to exercise its preferential subscription rights to participate in the convertible bond issuance of its associate company, Yongqi Electronics, with an investment of no more than 89.249 million yuan [3] - Dayou Energy's subsidiary Mengjin Coal Mine has resumed production after a 38-day suspension due to an accident, with an annual capacity of 1.2 million tons [5] - Shanying International plans to repurchase shares worth between 500 million and 1 billion yuan, with a maximum repurchase price of 2.50 yuan per share [7] Group 3 - Huatai Securities has been approved to issue up to 10 billion yuan in technology innovation bonds to support investment in the technology innovation sector [9] - Weixin Kang's cooperative product, an injectable multivitamin, has passed the consistency evaluation, enhancing its market potential [10] - Jinpu Titanium's controlling shareholder will have 35 million shares auctioned, accounting for 3.55% of the company's total share capital [11] Group 4 - China Pharmaceutical plans to waive its preferential purchase rights for a 24% stake in Chongqing Medical Health Industry Co., with a base transfer price of 2.206 billion yuan [12] - Beijia Clean plans to reduce its shareholding by 1.99% due to funding needs [13] - Anpelon has obtained a design patent for a brake sensor, enhancing its technological capabilities [14] Group 5 - Zhongyue Holdings' subsidiary has received approval for a clinical trial application for a new drug, indicating progress in its pharmaceutical development [14] - Lijun Group's YJH-012 injection has been approved for clinical trials, showcasing its potential in treating gout [16] - Yageer has sold financial assets totaling 4.176 billion yuan, representing 10.13% of its audited net assets for 2024 [15] Group 6 - Tailing Micro expects a net profit increase of approximately 267% year-on-year for the first half of 2025, driven by customer demand and product sales [19] - Baotai plans to invest 287 million yuan to acquire a 51% stake in Shaanxi Wanhao Titanium Technology Co., enhancing its production capabilities [21] - Laime Pharmaceutical has received a drug registration certificate for azithromycin granules, expanding its product portfolio [23] Group 7 - KQ Bio has received approval for a new veterinary vaccine, marking a significant advancement in its product offerings [25] - Robotech signed a contract worth approximately 17.1 million euros, representing over 12.82% of its audited revenue for 2024 [26] - Alloy Investment is planning a control change, leading to a temporary suspension of its stock [27] Group 8 - Huabang Health's subsidiary has received approval for two dermatological drugs, indicating growth in its pharmaceutical pipeline [28] - Lingxiao Pump Industry plans to invest 60 million yuan in wealth management products, optimizing its financial strategy [29] - Jinzhong Technology has won projects totaling 113 million yuan, accounting for 6.39% of its expected revenue for 2024 [31] Group 9 - Yifan Pharmaceutical's subsidiary has received approval for a clinical trial of a growth hormone injection, indicating progress in its research and development [32] - Guiguan Electric plans to invest 395 million yuan in a photovoltaic project, reflecting its commitment to renewable energy [33] - Rili Technology intends to repurchase shares worth between 10 million and 20 million yuan, supporting its stock performance [34] Group 10 - Xingye Securities' chairman has resigned, leading to a change in leadership [35] - Jinko Solar has achieved third-party certification for its high-efficiency solar cells, setting a new industry record [37] - Changan Automobile's controlling shareholder has changed its name, reflecting a rebranding effort [38]

腾讯首款数字疗法进入临床应用 6月23日，腾讯云微信公众号发文显示，腾讯自主研发的认知功能训练软件"腾讯脑力锻炼"，获批广东 省药监局颁发的医疗器械注册证，将进入临床应用阶段，可以帮助轻度认知障碍患者有效改善认知能 力。 21点评：轻度认知障碍是阿尔茨海默病的前期阶段，表现为记忆、语言、注意力等认知功能下降，但还 没有严重到影响日常生活的能力。统计数据显示，国内轻度认知障碍的患者接近4000万人。在无干预的 情况下，有38%的患者会在5年内进展为阿尔茨海默病，给个人和社会带来不可估量的负担。 6月23日，国家卫生健康委官网发布关于通报表扬2022-2023年度全国平安医院建设表现突出地区、集体 和个人的通知显示，为鼓励表现突出的地区、集体和个人，激励广大基层干部职工更加积极主动投身平 安医院建设工作，经研究，决定对北京市通州区等61个地区、北京大学口腔医院等545个集体和张茂鑫 等572名个人予以通报表扬。希望受表扬的地区、集体和个人再接再厉、开拓创新、奋发进取，发挥好 榜样示范作用，为平安医院建设再创新功绩。 药械审批 政策动向 国家卫生健康委：通报表扬2022-2023年度全国平安医院建设表现突出地区、集 ...

据了解，本轮融资将用于推进公司在研产品管线开发，深化在严肃医疗及消费医疗领域的技术布局，加快公司产品管线临床进展、申报进程及市场推广。 君合盟生物制药（杭州）有限公司成立于2020年11月，是一家专注于重组蛋白创新药物及合成生物学领域创新产品开发的生物科技公司，凭借多年的重组蛋 白药物研发及产业化经验，实现了覆盖产品开发全流程的核心技术、平台及人才的积淀，形成了一套完整的技术及产品开发体系。 据介绍，君合盟的研发管线布局围绕严肃医疗、消费医疗、代谢等拥有广阔市场的前沿蛋白药物领域，已实现包括重组I/III型人胶原蛋白原液及制剂、重组 A型肉毒毒素等在内的高端重组蛋白产品的规模化放大，技术水平及产业化进展处于国际领先水平。其中，核心产品重组人生长激素注射液已完成III期临 床；重组A型肉毒毒素已于近日完成成人中重度眉间纹适应症III期临床的首例受试者给药，其用于成人脑卒中后上肢痉挛适应症的II期临床试验也已接近尾 声，即将进入到III期临床。 君合盟CEO徐葵表示：从成立以来，我们始终聚焦严肃医疗与消费医疗领域未满足的临床需求，以自主研发为核心驱动力，构建了覆盖重组蛋白药物全生命 周期的技术平台与产品管线。未来 ...